(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today released a schedule detailing research that will be presented by Edith Sanford Breast Cancer Research leaders at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium next week. The conference will run from December 10 – 14, in San Antonio, Texas.
Brian Leyland-Jones, MB BS, PhD, director of Edith Sanford Breast Cancer Research, will present four scientific abstracts highlighting emerging treatments for hard-to-treat cancers, such as triple negative breast cancer, and new insights on biologic targets and prevention.
Leyland-Jones will be joined by other members of the research team, including Casey Williams, PhD, clinical director of research; as well as Pradip De, PhD; Nandini Dey, PhD; and Yuliang Sun, MD, PhD.
Now in its 36th year, the annual symposium is the foremost gathering of scientists, physicians and health care professionals dedicated to ending breast cancer. It aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
The details of the Edith Sanford Breast Cancer Research presentations are as follows:
|Thursday, December 12, 2013|
Poster Session 3
|(P3-04-02) Absence of PTEN Facilitates the Anti-tumor Efficacy of GDC-0980 in Combination with ABT888 plus Carboplatin in BRCA1-competent Triple Negative Breast Cancer.Dey N, Sun Y, Carlson J, Friedman L, De P, Leyland-Jones B.||
Exhibit Halls A-B
|Friday, December 13, 2013|
General Session 5
|(S5-07) SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment.Smerage JB, Barlow WE, Hayes DF, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Gralow JR, Livingston RB, Hortobagyi GN.||
Exhibit Hall D
General Session 6
|(S6-05) High levels of APOBEC3B, a DNA deaminase and an enzymatic source of C-to-T transitions, are a validated marker of poor outcome in estrogen receptor-positive breast cancer.Sieuwerts AM, Burns M, Look MP, Meijer-Van Gelder ME, Schlicker A, Heidemann MR, Jacobs H, Wessels L, Willis S, Leyland-Jones B, Gray K, Foekens JA, Harris RS, Martens JW.||
Exhibit Hall D
Poster Session 5
|(P5-06-01) The PI3K inhibitor GDC-0941 combines with trastuzumab for superior anti-tumor efficacy in HER2+ breast cancer models.De P, Sun Y, Carlson J, Friedman L, Dey N, Leyland-Jones B.||
Exhibit Halls A-B
About the Edith Sanford Breast Cancer Foundation
The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations.
About Sanford Health
Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in nine states.